FN2 Earnings Intelligence
AbbVie Inc. earnings overview
Latest AbbVie Inc. (ABBV) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
AbbVie Inc.
The supplied analysis supports a constructive but conditional view: immunology growth, new approvals, and pipeline expansion strengthen AbbVie’s growth trajectory, while regulatory, competitive, and integration risks remain material.
AbbVie Inc.
AbbVie's Q1 FY2026 results reinforce the post-Humira transition thesis: Skyrizi and Rinvoq are delivering double-digit growth and gaining market share across psoriatic disease, IBD, and emerging dermatology indications, more than offsetting ongoing biosimilar erosion of Humira. With a raised full-year adjusted EPS guidance range of $14.08-$14.28, a deep pipeline spanning obesity (ABBV-295), oncology (Temab-A, PD-1/VEGF bispecifics), and neuroscience (tavapadon, VYALEV), and significant manufacturing capacity investments, management signaled confidence in sustained growth. The stock's +3.1% earnings-day move and +7.2% subsequent drift suggest the market is endorsing the beat-and-raise narrative.
AbbVie Inc.
The latest analysis supports a constructive but qualified view: resilient immunology and neuroscience growth, raised guidance and pipeline progress strengthen the growth case, while biosimilar erosion, pricing changes and aesthetics softness remain material counterweights.
AbbVie Inc.
The quarter supports a constructive operating thesis: resilient demand in Skyrizi, Rinvoq, neuroscience, and new products is being reinforced by pipeline activity and raised guidance. The thesis remains dependent on growth durability, pricing, biosimilar management, and execution against the expanding pipeline.
AbbVie Inc.
The supplied analysis supports a constructive but qualified view: Skyrizi and Rinvoq share gains, new indications and pipeline progress strengthen AbbVie’s growth platform, while Humira erosion, aesthetics weakness, pricing pressure and regulatory uncertainty limit the case.
AbbVie Inc.
The supplied analysis supports a constructive near-term earnings trajectory: strong Skyrizi and Rinvoq growth and repeated guidance increases are offsetting Humira erosion. Sustaining that trajectory depends on continued immunology momentum, pipeline execution, and resilience in aesthetics.
AbbVie Inc.
AbbVie's current analysis supports a growth-and-diversification thesis centered on Skyrizi and Rinvoq, pipeline progress and neuroscience expansion, but the outlook remains balanced by Humira erosion, policy pressure, aesthetics weakness in China and transaction-related costs.
Get the ABBV recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.